Pfizer's New Breast Cancer Drug Outperforms Existing Treatments in Women Who'd Already Failed Standard Therapy
Atirmociclib, a next-generation CDK4 inhibitor, significantly improved progression-free survival in hormone receptor-positive metastatic breast c…
March 21, 2026